Johnson & Johnson has announced new research data highlighting the performance of its ACUVUE OASYS MAX 1-Day for ASTIGMATISM contact lenses. The company stated that these lenses provide higher end-of-day comfort compared to Dailies Total1 for Astigmatism, according to adjusted survey scores. The findings will be presented at the American Academy of Optometry’s annual meeting in Boston.
The company also shared results on its ACUVUE OASYS MAX 1-Day MULTIFOCAL for ASTIGMATISM lens, which is designed for presbyopic patients who have astigmatism. This product extends daily disposable multifocal contact lens options to a broader group of patients.
Peter Menziuso, Company Group Chairman, Vision at Johnson & Johnson, said: “At Johnson & Johnson, our relentless pursuit of innovation drives us to develop solutions that truly transform lives and makes vision possible for more than 40 million people around the world. The ACUVUE OASYS MAX 1-Day family of contact lenses exemplifies our commitment to empowering more patients to see the world with clarity and confidence every day.”
Dr. Caroline Blackie, Vice President of Medical Affairs, Vision at Johnson & Johnson, added: “New data illustrates the superior advantages of our ACUVUE OASYS MAX 1-Day Contact Lens technology vs. competitive technology. The head-to-head data distinctly highlights the positive impact our lens technology has on patients’ vision, reaffirming our leadership in material sciences and contact lens innovation.”
One study found that 62% of participants preferred ACUVUE OASYS MAX 1-Day for ASTIGMATISM for overall vision compared to 18% who preferred Dailies Total1 for Astigmatism. In terms of comfort and digital device use, most users also favored the ACUVUE brand lens. Another analysis showed that when this lens was worn after trying another brand, positive feedback increased further.
Additional research indicates that the ACUVUE OASYS MAX 1-Day MULTIFOCAL for ASTIGMATISM provides similar vision quality as existing products but is suitable for those with higher levels of refractive astigmatism. This product is described by Johnson & Johnson as "the first and only daily disposable contact lens for people with both astigmatism and presbyopia." It is now available in several markets including the United States, Canada, EMEA and APAC regions.
For more information about these products or finding an eye care provider, consumers can visit https://www.ACUVUE.com/en-us/oasys-max/.
Johnson & Johnson emphasizes its long-standing role in developing products aimed at improving eye health globally through ongoing innovation in material and optical science.
The company reminds consumers that ACUVUE Contact Lenses are prescription-only medical devices and should be used under professional supervision due to potential risks associated with improper use.
Forward-looking statements regarding future performance are subject to various risks outlined in filings with U.S. securities regulators.